Lyell Wealth Management LP Grows Position in iShares Biotechnology ETF $IBB

Lyell Wealth Management LP grew its holdings in iShares Biotechnology ETF (NASDAQ:IBB) by 67.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,830 shares of the financial services provider’s stock after acquiring an additional 4,380 shares during the period. Lyell Wealth Management LP’s holdings in iShares Biotechnology ETF were worth $1,828,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also made changes to their positions in the business. BNP Paribas Financial Markets lifted its position in shares of iShares Biotechnology ETF by 11.4% in the fourth quarter. BNP Paribas Financial Markets now owns 2,133,461 shares of the financial services provider’s stock valued at $360,064,000 after acquiring an additional 218,066 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of iShares Biotechnology ETF by 27.2% in the third quarter. JPMorgan Chase & Co. now owns 1,060,048 shares of the financial services provider’s stock valued at $153,039,000 after acquiring an additional 226,852 shares in the last quarter. LPL Financial LLC lifted its position in shares of iShares Biotechnology ETF by 145.9% in the fourth quarter. LPL Financial LLC now owns 992,799 shares of the financial services provider’s stock valued at $167,555,000 after acquiring an additional 589,033 shares in the last quarter. Truist Financial Corp lifted its position in shares of iShares Biotechnology ETF by 2,239.6% in the fourth quarter. Truist Financial Corp now owns 642,023 shares of the financial services provider’s stock valued at $108,354,000 after acquiring an additional 614,582 shares in the last quarter. Finally, WestEnd Advisors LLC purchased a new position in shares of iShares Biotechnology ETF in the fourth quarter valued at about $106,276,000. 62.45% of the stock is currently owned by hedge funds and other institutional investors.

iShares Biotechnology ETF Stock Performance

Shares of iShares Biotechnology ETF stock opened at $170.49 on Friday. The stock’s 50-day simple moving average is $170.27 and its 200-day simple moving average is $170.65. iShares Biotechnology ETF has a 52 week low of $123.61 and a 52 week high of $179.64.

iShares Biotechnology ETF Cuts Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 20th. Stockholders of record on Tuesday, March 17th were given a $0.1218 dividend. This represents a $0.49 annualized dividend and a dividend yield of 0.3%. The ex-dividend date was Tuesday, March 17th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.